socalTECH

OCTOBER 18, 2012

San Diego-based venture investor Avalon Ventures has backed a developer of video advertising products, Selectable Media , to the tune of $2M. Selectable Media, which is based in New York, lets users opt into branded video advertising in exchange for free access to content on web and mobile apps. READ MORE>>.

Avalon 147

Avalon Media San Diego Advertising 147

socalTECH

JUNE 15, 2015

San Diego-based Avalon Ventures said this morning that it has launched and funded three, new companies as part of its deal with GSK. Avalon Venturs said that Adrenergics , CadheRx Therapeutics , and Calporta Therapeutics have all received $10M in Series A funding, and will receive R&D support from Avalon Ventures and GSK.

Avalon 100

Avalon San Diego Startup Funding 100

socalTECH

JULY 18, 2013

in venture capital investments in Q2 2013 across Southern California, spread across 80 deals. However, venture dollars invested were above Q1, when Southern California saw $569.1M However, venture dollars invested were above Q1, when Southern California saw $569.1M in investments across 90 deals.

Southern California 187

Southern California Venture Capital Tech Coast Angels Capital 187

Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56

Avalon Invest Southern California Develop 56

socalTECH

OCTOBER 22, 2014

San Diego-based StackIQ , which develops IT automation tools for the enterprise, has raised $6M in a Series B funding round, according to the company. The new funding came from Grayhawk Capital, Keshif Ventures, DLA Piper, and OurCrowd, as well as Anthem Venture Partners and Avalon Ventures. READ MORE>>.

Avalon 174

Avalon Anthem San Diego Venture Capital 174

socalTECH

SEPTEMBER 10, 2014

San Diego-based Avelas Biosciences , which is developing cell penetrating peptides to light up cancerous tissue in patients during surgery, has raised $7.4M The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments. in a Series B funding.

Avalon 147

Avalon San Diego Venture Capital Research 147

socalTECH

MARCH 29, 2021

San Diego-based Fortis Therapeutics, a biotechnology startup developing treatments for late-stage prostate cancer and multiple myeloma, has raised $40M in a Series A financing, the company said on Monday.

Avalon 113

Avalon San Diego Research Funding 113

socalTECH

JULY 17, 2014

The latest venture capital totals from the PricewaterhouseCoopers/National Venture Capital Association''s MoneyTree Report was released this evening, tallying up $761.12M in investments in Q2 of 2014 in Southern California, up from Q2 of 2013, when $616.83M was invested in the region.

Southern California 240

Southern California El Segundo Culver City Orange County 240

socalTECH

MARCH 13, 2014

San Diego-based AnaptysBio , a biopharmaceuticals firm focused on the development of therapeutic antibodies, announced a deal today with TESARO. According to AnaptysBio, it will receive an upfront license fee of $17M from TESARO, plus receive funding of costs incurred in related development programs, as part of an antibody program.

Avalon 138

Avalon San Diego Venture Capital Research 138

socalTECH

JULY 28, 2020

San Diego-based telemedicine and telehealth software developer AristaMD has added another $6M to the company's Series B, bringing the total to $24M, the company said on Monday. The funding came from Ascension Ventures and.406 The funding came from Ascension Ventures and.406 The company is led by CEO Brooke LeVasseur.

Funding 100

Funding Avalon San Diego Software Development 100

socalTECH

AUGUST 30, 2010

San Diego-based Otonomy , a biopharmaceuticals firm developing products to treat disorders of the inner and middle ear, announced today that it has raised $38.5M The round was led by Novo Ventures and RiverVest Venture Partners, and also includes Domain Associates, TPG Biotech, and Avalon Ventures.

Avalon 150

Avalon San Diego Venture Capital Study 150

socalTECH

JULY 21, 2011

San Diego-based Amira Pharmaceuticals , a developer of small molecule pharmaceuticals for treating inflammatory and fibrotic diseases, has agreed to be acquired by Bristol-Myers Squibb , the firms said late Thursday. Amira Pharmaceuticals was venture backed by Avalon Ventures, Novo A/S,Prospect Venture Partners, and Versant Ventures.

Avalon 150

Avalon San Diego Venture Capital Capital 150

socalTECH

JUNE 9, 2010

San Diego-based Otonomy , a biopharmaceuticals firm developing drug therapies to treat inner and middle ear disorders, has raised $10.56M as part of an ongoing, $26.0M Source of the new funding was not disclosed, however, one of its founders, Jay Lichter, is at San Diego venture firm Avalon Ventures, which has previously backed the company.

Avalon 159

Avalon San Diego Venture Capital Capital 159

socalTECH

JUNE 9, 2009

San Diego-based aFraxis , a stealth-mode firm developing treatments for Fragile X Syndome and autism, has raised $750,000 in a funding round, according to a regulatory filing by the firm Tuesday. Details on the funding have not been announced, however, the company is venture backed by Avalon Ventures.

Avalon 100

Avalon San Diego Venture Capital Capital 100

socalTECH

DECEMBER 6, 2012

The funding came from Avalon Ventures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients. The firm's technology is based on technology developed by Nobel Prize winner Roger Tsien, Ph.D. READ MORE>>.

Avalon 138

Avalon San Diego Study Technology 138

socalTECH

MARCH 5, 2013

San Diego-based Carolus Therapeutics , a developer of biopharmaceuticals aimed at treating acute and chronic inflammation, has scored $2.25M in a debt funding round, according to financing provider Square 1 Bank. According to Square 1, the new funding will go support future growth at Carolus. READ MORE>>.

Avalon 147

Avalon Funding San Diego Develop 147

socalTECH

JUNE 1, 2010

Chumby develops a Wi-Fi enabled, Internet device which acts both as a clock as well as a connection into internet services like Weather, news, and more. Tags: chumby venture capital linux internet electronic device consumer. According to the filing, the firm is in the midst of raising up to $9.786M in the round. READ MORE>>.

Avalon 150

Avalon San Diego Venture Capital News 150

socalTECH

OCTOBER 4, 2010

Chumby has previously raised funding from Avalon Ventures, JK&B Capital, Masthead Venture Partners, and O'Reilly AlphaTech Ventures. Tags: chumby venture capital software internet electronics device linux. Source of the new funding was not disclosed. The company is headed by Derrick Oien.

Avalon 145

Avalon San Diego Venture Capital Software 145

socalTECH

DECEMBER 4, 2015

The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types.

UCLA 100

UCLA Avalon San Diego Los Angeles 100

socalTECH

JUNE 29, 2009

San Diego-based Ambit Biosciences , a developer of small molecule profiling tools being used for biopharmaceuticals development, has raised $6.5M Tags: ambit biosciences venture capital debt funding biopharmaceuticals lifescience. in an ongoing, debt round, according to a filing from the firm today.

Avalon 100

Avalon San Diego Venture Capital Tool 100

Xconomy

AUGUST 17, 2016

It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp., and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal.

Avalon 40

Avalon San Diego Study Invest 40

socalTECH

APRIL 1, 2013

San Diego-based Proximal Data , which develops serve-side caching software for accelerating I/O access to virtualized machines, said this morning that it has raised $2M in a Series B round of funding. The funding came from Divergent Ventures, along with existing investors Avalon Ventures.

Software 124

Software Avalon San Diego Design 124

socalTECH

JUNE 3, 2011

San Diego-based Otonomy , a firm developing products to treat disorders of the inner and middle ear, looks to have pulled in $14.2M in a round led by Novo Ventures and RiverVest Venture Partners, and which also included Domain Associates, TPG Biotech, and Avalon Ventures. out of a $38.8M

Funding 140

Funding Avalon San Diego Product 140

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. We really have a development focus,” Martin told me. “We But it’s structured differently.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

socalTECH

NOVEMBER 18, 2008

According to the firm, the financing came from Avalon Ventures LLC. Zacharon Pharmaceutical is developing glycan inhibitors which have appications in treating genetic disorders and oncology. San Diego-based Zacharon Pharmaceutical said today that it has raised $3.5M The firm also said it has received more than $2.2M

Avalon 100

Avalon San Diego Research Technology 100

Xconomy

JULY 19, 2016

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

NOVEMBER 14, 2018

The San Diego-based company says it wants to use the proceeds to put its lead product candidate, an investigational cancer therapy that’s based on the drug interleukin-2 (IL-2), through dose escalation and expansion trials, and to develop products based on the same compound to treat autoimmune disorders.

San Diego 76

San Diego Product Develop Development 76

Xconomy

DECEMBER 7, 2018

Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.

Technology 98

Technology Develop Development San Diego 98